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During most of the last century, verification of patient position on the radiotherapy treatment table
was considered adequate if exposed on a photographic film by a megavoltage beam. It was a general
standard to expose such a film once a week, to be approved by a radiation oncologist. The latter
approved it after comparison to a kilovoltage simulation film exposed at the time of initial setup of
the patient before the treatment regimen started.
A common rule was to allow a <5mm variation from the simulation to the treatment portal
film. This often resulted in either an approval for the next week’s treatment fractions or a rejection
and retake of that or the next day’s portal film. There was no film record of the next four fractions.
The problems included megavoltage film resolution judged from kilovoltage simulation films as
well as unrecorded possible errors for the next four fractions. Another error source was soft tissue
contrast in both of these films.
The evolution of computerized axial tomography (CAT) scan from the mid-twentieth century
has allowed for 3D reconstruction of the patient’s soft tissue structures by improved resolution in
millimeter scan slices.
Development of the digital image visualization on computer screens now allows for fusing
the reconstructed simulation image (DRR) from the CAT scanner with the mega- or kilovoltage
rendering of the patient’s treatment beams. This has allowed the skilled radiotherapist to adjust
the beam within a preset millimeter 3D frame to the patient’s anatomy. With this precision, a daily
treatment fraction is given. The radiation oncologist can then check that body position errors have
been corrected before each treatment.
Further improvement include the cone beam image obtained from the treatment accelerator and
fused over the DRR, introduction of gold markers in the target volume and triangulating their
positions into the simulation scan, as well as utilizing kilovoltage and ormegavoltage images to attain
precise beam geometry for each daily radiotherapy fraction. Another method is to use a diagnostic
CAT scanner that is mechanically attached to the accelerator.
These imaging techniques are used to assure that the planned dose only covers the intended target
and encompasses the IGRT concept in radiotherapy. If used properly, the precision of treatment is
improved from centimeter to millimeter realms (1) and is expected to be used globally in cancer
radiotherapy. Our experience is that few treatment portals need to be rejected as long as there is a
requirement of immediate report to the oncologist that a specified position error has been discovered
and corrected.
We consider it a necessary ingredient for clinical studies in order to measure and compare IGRT
outcome data. It has the potential of not only providing better toxicity results but also to give better
outcome data for patient groups who are thought to be at higher risk for toxicity, e.g., frail elderly
and patients with abnormal radiosensitivity. It may also offer an avenue for dose escalation because
of better organ sparing.
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Our preliminary evidence is encouraging for the use
of IGRT.
Elderly (>70 years of age) and younger head and neck cancer
groups both tolerated definitive chemo-IGRT, without difference
in grade 3–4 toxicity, treatment breaks, and with less weight loss
in the elderly group (2). Another study resulted in disease-specific
survival of 75% at 4 years and acceptable toxicity (3).
Elderly patients with multiple comorbidities and locally
advanced rectal cancer tolerated preoperative chemo-IGRT when
compared to younger patients (4). These preliminary studies sug-
gest that IGRT may become the treatment of choice for elderly
cancer patients.
Another subset of patients who may benefit from IGRT
is patients with human immunodeficiency virus (HIV) infec-
tion and anal cancer. They may have an increased sensitivity
to radiation because of thiol deficiency (5). Grade 3–4 skin,
hematologic and gastrointestinal toxicity were frequent among
HIV positive patients undergoing standard chemoradiotherapy
and may result in death (6, 7). Chemo-IGRT may therefore
provide HIV patients the opportunity to be treated with less
toxicity (8, 9).
Finally, IGRTmay allow for radiation dose escalation in cancers
with high-risk for loco-regional recurrences. A recent randomized
study reported a 2-year survival of 57 and 44% and local failure
of 30 and 38% for locally advanced NSCLC treated to 60 and
74Gy, respectively. The poor survival in the 74Gy group may be
associated with cardiac toxicity (10).
A 3-year survival of 45% and local failure of 15% was reported
for patients with locally advanced NSCLC treated to 70–75Gy
with chemo-IGRT, with minimal toxicity (11). Dose escalation
was also feasible in patients with locally advanced esophageal
cancer because of lung and cardiac sparing (12).
These preliminary results are intriguing but need to be corrob-
orated in future prospective studies.
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